1
NSG 526 Exam 2: Comprehensive Examination
Psychiatric-Mental Health Nurse Practitioner
(PMHNP) — 2026/2027 Academic Year
DOMAIN 1: Advanced Psychopharmacology & the Neurotransmitters (18 Questions)
Sub-Topic 1.1: SSRI Mechanism & Therapeutic Timeline (4 Questions)
Question 1 (Multiple-Choice)
A 34-year-old patient with Major Depressive Disorder is prescribed fluoxetine 20 mg daily. The
patient asks the PMHNP, "How does this medication actually work in my brain?" Which
mechanism best describes the primary pharmacologic action of fluoxetine?
A. Fluoxetine blocks the postsynaptic serotonin receptors, preventing serotonin from binding
and reducing synaptic activity.
B. Fluoxetine inhibits the presynaptic serotonin transporter (SERT), increasing serotonin
concentration within the synaptic cleft. [CORRECT]
C. Fluoxetine increases the synthesis of serotonin in the raphe nuclei by upregulating
tryptophan hydroxylase activity.
D. Fluoxetine blocks the reuptake of both norepinephrine and dopamine equally, producing a
triaminergic effect.
Rationale: Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that exerts its therapeutic
effect by competitively inhibiting the presynaptic serotonin transporter (SERT). By blocking SERT,
fluoxetine prevents the reuptake of serotonin from the synaptic cleft back into the presynaptic
neuron, thereby increasing the concentration and duration of serotonin available to bind to
postsynaptic 5-HT receptors. This enhanced serotonergic neurotransmission occurs at the
synaptic level and is the foundational mechanism underlying the antidepressant effect of all
SSRIs.
Question 2 (Select-All-That-Apply)
,2
A 29-year-old patient with Major Depressive Disorder begins fluoxetine 20 mg daily. Which
statements regarding the expected therapeutic timeline are correct? Select all that apply.
A. The patient should expect to experience the full therapeutic antidepressant effect within 3 to
5 days of initiating therapy.
B. Initial improvement in sleep and appetite may be observed within the first 1 to 2 weeks of
treatment. [CORRECT]
C. The full therapeutic response for depressive symptom remission typically requires 4 to 6
weeks of continuous SSRI therapy. [CORRECT]
D. Serotonin receptor downregulation and neuroplastic changes in the prefrontal cortex occur
over several weeks and correlate with the delayed onset of full therapeutic efficacy. [CORRECT]
E. If no improvement is seen by week 2, the medication should be immediately discontinued
and switched to a different class.
Rationale: The therapeutic timeline of SSRIs is characterized by a delayed onset of full
antidepressant effect. While some patients may experience early improvements in
neurovegetative symptoms (sleep, appetite, energy) within 1–2 weeks, the complete remission
of depressive symptoms requires 4–6 weeks of continuous treatment. This delay is attributed to
downstream neuroadaptive changes, including desensitization of somatodendritic 5-HT1A
autoreceptors, enhanced postsynaptic serotonergic signaling, and neuroplastic changes in
corticolimbic circuits. Premature discontinuation before the 4–6 week window is a common
clinical error that leads to unnecessary medication switches.
Question 3 (Multiple-Choice)
The PMHNP is educating a patient about the mechanism of fluoxetine. The patient states, "So
this medication makes my brain produce more serotonin, right?" Which response by the
PMHNP best corrects this misconception while accurately describing the pharmacologic
mechanism?
A. "Yes, that's correct—fluoxetine stimulates the raphe nuclei to synthesize more serotonin from
tryptophan."
B. "Not exactly. Fluoxetine doesn't increase serotonin production; it blocks the presynaptic
serotonin transporter (SERT), which allows serotonin to remain in the synaptic cleft longer and
enhance receptor signaling." [CORRECT]
C. "Actually, fluoxetine works by blocking postsynaptic serotonin receptors, which paradoxically
reduces serotonin signaling and relieves depression."
D. "Fluoxetine primarily works on dopamine pathways in the nucleus accumbens, which is why
it's also used for addiction."
,3
Rationale: A common patient misconception is that SSRIs increase serotonin synthesis. The
PMHNP must clarify that fluoxetine does NOT increase serotonin production; rather, it blocks
the presynaptic serotonin transporter (SERT), which is responsible for reuptaking serotonin from
the synaptic cleft. By inhibiting SERT, fluoxetine increases the synaptic concentration of pre-
existing serotonin and prolongs its availability for postsynaptic receptor binding. This distinction
is clinically important because it explains why SSRIs do not cause serotonin depletion with long-
term use and why their effect is dependent on existing serotonergic neuron function.
Question 4 (Calculation)
A 45-year-old patient has been on fluoxetine 20 mg daily for 3 weeks with partial response. The
PMHNP decides to increase the dose. The patient asks when the full therapeutic effect of the
new dose can be expected. If the current date is Day 21 of therapy, and the dose increase occurs
today, calculate the minimum number of additional days required before the patient can expect
the full therapeutic response from the new dose, based on the established 4–6 week onset
timeline.
A. 7 days
B. 14 days
C. 21 days [CORRECT]
D. 42 days
Rationale: The full therapeutic response timeline of 4–6 weeks (28–42 days) applies from the
initiation of therapeutic dosing. Since the patient has already completed 21 days at the initial
dose, the minimum additional time required to reach the 4-week (28-day) threshold is 28 − 21 =
7 days. However, because a dose increase essentially "resets" the timeline for achieving the full
response at the new therapeutic level, the conservative clinical approach is to allow another 3
weeks (21 days) for the new dose to achieve its full effect, bringing the total to 6 weeks. The
most clinically accurate answer reflecting the need for an additional complete therapeutic
window is 21 days, ensuring the patient reaches the full 6-week benchmark for dose-adjusted
therapy.
Sub-Topic 1.2: Serotonin Syndrome — Clinical Presentation & Emergency Management (4
Questions)
Question 5 (Multiple-Choice)
A 52-year-old patient on sertraline 200 mg daily is admitted to the emergency department after
starting tramadol for postoperative pain 48 hours ago. The patient presents with agitation,
, 4
diaphoresis, temperature of 40.1°C (104.2°F), and bilateral lower extremity hyperreflexia with
inducible clonus. Which is the priority nursing action?
A. Administer propranolol 1 mg IV to block peripheral adrenergic symptoms.
B. Immediately discontinue all serotonergic agents and initiate external cooling measures.
[CORRECT]
C. Administer haloperidol 5 mg IM to control the agitation and prevent progression to
neuroleptic malignant syndrome.
D. Increase the sertraline dose to counteract the tramadol-induced serotonin depletion.
Rationale: Serotonin syndrome is a life-threatening condition caused by excessive serotonergic
agonism, most commonly due to drug interactions (e.g., SSRI + tramadol, SSRI + MAOI, SSRI + St.
John's wort). The Hunter Serotonin Toxicity Criteria require the presence of clonus
(spontaneous, inducible, or ocular) plus agitation, diaphoresis, tremor, hyperreflexia, or
hyperthermia. The immediate management priority is the cessation of ALL serotonergic agents
and supportive care, including external cooling for hyperthermia, IV hydration, and
cardiorespiratory monitoring. Cyproheptadine (a 5-HT2A antagonist) may be used as an
antidote in severe cases. Propranolol is not first-line; haloperidol is contraindicated as it may
worsen symptoms or cause NMS confusion.
Question 6 (Select-All-That-Apply)
A PMHNP is assessing a patient in the emergency department for serotonin syndrome. Which
clinical findings are consistent with the neuromuscular and autonomic criteria of the Hunter
Serotonin Toxicity Criteria? Select all that apply.
A. Bilateral hyperreflexia with sustained ankle clonus after gentle dorsiflexion of the foot.
[CORRECT]
B. Temperature of 39.8°C (103.6°F) with profuse diaphoresis. [CORRECT]
C. Severe rigidity of all four extremities with lead-pipe rigidity and bradykinesia.
D. Agitation with restlessness and pressured speech. [CORRECT]
E. Mydriasis and dry mucous membranes. [CORRECT]
Rationale: The Hunter Serotonin Toxicity Criteria are the gold standard for diagnosing serotonin
syndrome. The criteria require clonus (spontaneous, inducible, or ocular) PLUS either agitation,
diaphoresis, tremor, hyperreflexia, or hyperthermia. Key features include: neuromuscular
hyperreflexia (especially lower extremities), clonus (hallmark finding), hyperthermia (due to
increased muscle activity and hypothalamic dysregulation), autonomic instability (diaphoresis,
mydriasis, tachycardia, hypertension), and mental status changes (agitation, confusion). Severe
NSG 526 Exam 2: Comprehensive Examination
Psychiatric-Mental Health Nurse Practitioner
(PMHNP) — 2026/2027 Academic Year
DOMAIN 1: Advanced Psychopharmacology & the Neurotransmitters (18 Questions)
Sub-Topic 1.1: SSRI Mechanism & Therapeutic Timeline (4 Questions)
Question 1 (Multiple-Choice)
A 34-year-old patient with Major Depressive Disorder is prescribed fluoxetine 20 mg daily. The
patient asks the PMHNP, "How does this medication actually work in my brain?" Which
mechanism best describes the primary pharmacologic action of fluoxetine?
A. Fluoxetine blocks the postsynaptic serotonin receptors, preventing serotonin from binding
and reducing synaptic activity.
B. Fluoxetine inhibits the presynaptic serotonin transporter (SERT), increasing serotonin
concentration within the synaptic cleft. [CORRECT]
C. Fluoxetine increases the synthesis of serotonin in the raphe nuclei by upregulating
tryptophan hydroxylase activity.
D. Fluoxetine blocks the reuptake of both norepinephrine and dopamine equally, producing a
triaminergic effect.
Rationale: Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that exerts its therapeutic
effect by competitively inhibiting the presynaptic serotonin transporter (SERT). By blocking SERT,
fluoxetine prevents the reuptake of serotonin from the synaptic cleft back into the presynaptic
neuron, thereby increasing the concentration and duration of serotonin available to bind to
postsynaptic 5-HT receptors. This enhanced serotonergic neurotransmission occurs at the
synaptic level and is the foundational mechanism underlying the antidepressant effect of all
SSRIs.
Question 2 (Select-All-That-Apply)
,2
A 29-year-old patient with Major Depressive Disorder begins fluoxetine 20 mg daily. Which
statements regarding the expected therapeutic timeline are correct? Select all that apply.
A. The patient should expect to experience the full therapeutic antidepressant effect within 3 to
5 days of initiating therapy.
B. Initial improvement in sleep and appetite may be observed within the first 1 to 2 weeks of
treatment. [CORRECT]
C. The full therapeutic response for depressive symptom remission typically requires 4 to 6
weeks of continuous SSRI therapy. [CORRECT]
D. Serotonin receptor downregulation and neuroplastic changes in the prefrontal cortex occur
over several weeks and correlate with the delayed onset of full therapeutic efficacy. [CORRECT]
E. If no improvement is seen by week 2, the medication should be immediately discontinued
and switched to a different class.
Rationale: The therapeutic timeline of SSRIs is characterized by a delayed onset of full
antidepressant effect. While some patients may experience early improvements in
neurovegetative symptoms (sleep, appetite, energy) within 1–2 weeks, the complete remission
of depressive symptoms requires 4–6 weeks of continuous treatment. This delay is attributed to
downstream neuroadaptive changes, including desensitization of somatodendritic 5-HT1A
autoreceptors, enhanced postsynaptic serotonergic signaling, and neuroplastic changes in
corticolimbic circuits. Premature discontinuation before the 4–6 week window is a common
clinical error that leads to unnecessary medication switches.
Question 3 (Multiple-Choice)
The PMHNP is educating a patient about the mechanism of fluoxetine. The patient states, "So
this medication makes my brain produce more serotonin, right?" Which response by the
PMHNP best corrects this misconception while accurately describing the pharmacologic
mechanism?
A. "Yes, that's correct—fluoxetine stimulates the raphe nuclei to synthesize more serotonin from
tryptophan."
B. "Not exactly. Fluoxetine doesn't increase serotonin production; it blocks the presynaptic
serotonin transporter (SERT), which allows serotonin to remain in the synaptic cleft longer and
enhance receptor signaling." [CORRECT]
C. "Actually, fluoxetine works by blocking postsynaptic serotonin receptors, which paradoxically
reduces serotonin signaling and relieves depression."
D. "Fluoxetine primarily works on dopamine pathways in the nucleus accumbens, which is why
it's also used for addiction."
,3
Rationale: A common patient misconception is that SSRIs increase serotonin synthesis. The
PMHNP must clarify that fluoxetine does NOT increase serotonin production; rather, it blocks
the presynaptic serotonin transporter (SERT), which is responsible for reuptaking serotonin from
the synaptic cleft. By inhibiting SERT, fluoxetine increases the synaptic concentration of pre-
existing serotonin and prolongs its availability for postsynaptic receptor binding. This distinction
is clinically important because it explains why SSRIs do not cause serotonin depletion with long-
term use and why their effect is dependent on existing serotonergic neuron function.
Question 4 (Calculation)
A 45-year-old patient has been on fluoxetine 20 mg daily for 3 weeks with partial response. The
PMHNP decides to increase the dose. The patient asks when the full therapeutic effect of the
new dose can be expected. If the current date is Day 21 of therapy, and the dose increase occurs
today, calculate the minimum number of additional days required before the patient can expect
the full therapeutic response from the new dose, based on the established 4–6 week onset
timeline.
A. 7 days
B. 14 days
C. 21 days [CORRECT]
D. 42 days
Rationale: The full therapeutic response timeline of 4–6 weeks (28–42 days) applies from the
initiation of therapeutic dosing. Since the patient has already completed 21 days at the initial
dose, the minimum additional time required to reach the 4-week (28-day) threshold is 28 − 21 =
7 days. However, because a dose increase essentially "resets" the timeline for achieving the full
response at the new therapeutic level, the conservative clinical approach is to allow another 3
weeks (21 days) for the new dose to achieve its full effect, bringing the total to 6 weeks. The
most clinically accurate answer reflecting the need for an additional complete therapeutic
window is 21 days, ensuring the patient reaches the full 6-week benchmark for dose-adjusted
therapy.
Sub-Topic 1.2: Serotonin Syndrome — Clinical Presentation & Emergency Management (4
Questions)
Question 5 (Multiple-Choice)
A 52-year-old patient on sertraline 200 mg daily is admitted to the emergency department after
starting tramadol for postoperative pain 48 hours ago. The patient presents with agitation,
, 4
diaphoresis, temperature of 40.1°C (104.2°F), and bilateral lower extremity hyperreflexia with
inducible clonus. Which is the priority nursing action?
A. Administer propranolol 1 mg IV to block peripheral adrenergic symptoms.
B. Immediately discontinue all serotonergic agents and initiate external cooling measures.
[CORRECT]
C. Administer haloperidol 5 mg IM to control the agitation and prevent progression to
neuroleptic malignant syndrome.
D. Increase the sertraline dose to counteract the tramadol-induced serotonin depletion.
Rationale: Serotonin syndrome is a life-threatening condition caused by excessive serotonergic
agonism, most commonly due to drug interactions (e.g., SSRI + tramadol, SSRI + MAOI, SSRI + St.
John's wort). The Hunter Serotonin Toxicity Criteria require the presence of clonus
(spontaneous, inducible, or ocular) plus agitation, diaphoresis, tremor, hyperreflexia, or
hyperthermia. The immediate management priority is the cessation of ALL serotonergic agents
and supportive care, including external cooling for hyperthermia, IV hydration, and
cardiorespiratory monitoring. Cyproheptadine (a 5-HT2A antagonist) may be used as an
antidote in severe cases. Propranolol is not first-line; haloperidol is contraindicated as it may
worsen symptoms or cause NMS confusion.
Question 6 (Select-All-That-Apply)
A PMHNP is assessing a patient in the emergency department for serotonin syndrome. Which
clinical findings are consistent with the neuromuscular and autonomic criteria of the Hunter
Serotonin Toxicity Criteria? Select all that apply.
A. Bilateral hyperreflexia with sustained ankle clonus after gentle dorsiflexion of the foot.
[CORRECT]
B. Temperature of 39.8°C (103.6°F) with profuse diaphoresis. [CORRECT]
C. Severe rigidity of all four extremities with lead-pipe rigidity and bradykinesia.
D. Agitation with restlessness and pressured speech. [CORRECT]
E. Mydriasis and dry mucous membranes. [CORRECT]
Rationale: The Hunter Serotonin Toxicity Criteria are the gold standard for diagnosing serotonin
syndrome. The criteria require clonus (spontaneous, inducible, or ocular) PLUS either agitation,
diaphoresis, tremor, hyperreflexia, or hyperthermia. Key features include: neuromuscular
hyperreflexia (especially lower extremities), clonus (hallmark finding), hyperthermia (due to
increased muscle activity and hypothalamic dysregulation), autonomic instability (diaphoresis,
mydriasis, tachycardia, hypertension), and mental status changes (agitation, confusion). Severe
